Daniel Rea

TL;DR: Everolimus was satisfactorily tolerated at dosages up to 70 mg/wk and 10 mg/d with predictable PK and Antitumor activity and PD in tumors require further clinical investigation.

TL;DR: ATTom confirms that, in ER+ disease, continuing tamoxifen to year 10 rather than just to year 5 produces further reductions in recurrence, from year 7 onward, and breast cancer mortality after year 10.

TL;DR: Among patients receiving chemotherapy for solid tumors or lymphoma, the prophylactic use of levofloxacin reduces the incidence of fever, probable infection, and hospitalization.

TL;DR: In the safety analysis, sequential treatment was associated with a higher incidence of gynaecological symptoms and endometrial abnormalities than was exemestane alone, and treatment regimens of exemstane alone or after tamoxifen might be appropriate options for postmenopausal women with hormone-receptor-positive early breast cancer.

TL;DR: The background and development of 'The low risk' DCIS trial (LORIS), a phase III trial of surgery versus active monitoring, will determine if it is appropriate to manage women with screen detected or asymptomatic, low grade and intermediate grade DCIS with low grade features, by active monitoring rather than by surgical treatment.